Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial
Yunpeng Yang(Sun Yat-sen University), Li Zhang(Jinan Stomatological Hospital), Yiping Zhang(National Health and Family Planning Commission), Weineng Feng(First People's Hospital of Foshan), Giovanni Selvaggi, Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yi Hu(Union Hospital), Zhendong Zheng(General Hospital of Shenyang Military Region), Yanqiu Zhao(Henan Cancer Hospital), Gang Wu(Hubei University of Chinese Medicine), Youling Gong(Dalian Medical University), Kewei Ma(Jilin University), Wei Song(Xuzhou Medical College), Shijun Zhao(Second Hospital of Shandong University), Shanshan Xiao(Central South University), Yubiao Guo(Sun Yat-sen University), Jian Fang(Peking University), Jianhua Chen(Hunan Cancer Hospital), Yuan Chen(China General Nuclear Power Corporation (China)), Tao Wang(Pfizer (United States)), Feng Ye(Yangtze University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Zhuang Yu(Shanghai East Hospital), Jing Zheng(Zhejiang University), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Gaofeng Li, Jifeng Feng(Zhejiang Cancer Hospital), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Jie Huang(Sun Yat-sen University), Li Mao(Washington State University), Ning Wu(Regeneron (United States)), Lieming Ding(Betta Pharmaceuticals (China)), Wu Zhuang(Hunan University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Larry Zhu(Betta Pharmaceuticals (China)), Xiaoqing Liu(Chinese PLA General Hospital), Jianya Zhou(First Affiliated Hospital Zhejiang University)
Cited by 4
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k